No study left behind: A network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data

Value in Health

Volumn 12, Issue 6, 2009, Pages 996-1003

  Hawkins, Neil ^a   Scott, David A ^a   Woods, Beth S ^a   Thatcher, Nicholas ^b  

^a ICON PLC   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Indirect comparison; Mixed treatment comparisons; Network meta analysis; Non small cell lung cancer

Indexed keywords

DOCETAXEL; ERLOTINIB; GEFITINIB; PEMETREXED; PLACEBO;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CLINICAL RESEARCH; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIAS (EPIDEMIOLOGY); CARCINOMA, NON-SMALL-CELL LUNG; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TAXOIDS; YOUNG ADULT;

EID: 67651208796     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00541.x     Document Type: Article

References (28)

1. National Institute for Health and Clinical Excellence. Final Appraisal Determination - Erlotinib for the Treatment of Non-Small-Cell Lung Cancer. Technical Report. London : NICE, 2007.
2. Malone DC. Using indirect comparisons in pharmacoeconomic studies-time for implementation. Clin Ther 2007 29 : 2454 5.
3. Ioannidis JPA. Indirect comparisons: the mesh and mess of clinical trials. Lancet 2006 368 : 1470 2.
4. Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005 331 : 897 900.
5. McQuay H, Moore A. Utility of clinical trial results for clinical practice. Eur J Pain 2007 11 : 123 4.
6. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003 326 : 472 6.
7. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005 9 : 1 152.
8. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' guides to the medical literature: XIX. Applying clinical trial results B: guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999 282 : 1371 7.
9. Daya S. Adjusted indirect comparison of competing interventions. Evid Based Obstet Gynecol 2004 6 : 103 4.
10. Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 2008 61 : 455 63.
11. Ades AE, Sculpher MJ, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006 24 : 1 19.
12. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004 23 : 3105 24.
13. ASCO. ASCO annual meeting, virtual meeting: lung cancer track. Available from: http://www.asco.org/portal/site/ASCO/menuitem. 64cfbd0f85cb37b2eda2be0aee37a01d/?vgnextoid= 09f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=vm-track-sessions- view&index=y&confID=47&trackID=8 [Accessed January 11, 2007 D, Jadad AR, Nichol G, et al. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials 1995 16 : 62 73.
14. Spiegelhalter DJ, Thomas A, Best N, Lunn D. WinBUGS User Manual: Version 1.4. Cambridge : MRC Biostatistics Unit, 2003.
15. Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998 7 : 434 55.
16. Cufer T, Vrdoljak E, Gaafar R, et al. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006 17 : 401 9.
17. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004 22 : 1589 97.
18. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000 18 : 2095 103.
19. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 353 : 123 32.
20. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung cancer). Lancet 2005 366 : 1527 37.
21. Karrison TG, Maitland ML, Stadler WM, et al. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 2007 99 : 1455 61.
22. Scagliotti G. An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer. Expert Opin Pharmacother 2005 6 : 2855 66.
23. Niho S, Ichinose Y, Tamura T. Results of a randomized phase iii study to compare the overall survival of gefitinib (iressa) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens. In ASCO Annual Meeting, 2007. Available from: http://www.asco.org/ portal/site/ASCO/menuitem.64cfbd0f85cb37b2eda2be0aee37a01d/?vgnextoid= 09f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=vm-trach-sessions- view&index=y&confID=47&trackID=8 [Accessed January 11, 2007].
24. Douillard JY, Kim ES, Hirsh V. Gefitinib (iressa) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label phase iii study (interest). In 12th World Conference on Lung Cancer, 2007. Available from: http://www.2007worldlungcancer.org/ [Accessed January 11, 2007].
25. Shepherd FA. Discussion. In 12th World Conference on Lung Cancer, 2007. Available from: http://www.2007worldlungcancer.org/ [Accessed January 11, 2007].
26. Ades AE, Claxton K, Sculphur M. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. Health Econ 2006 15 : 373 81.
27. Riley RD, Lambert PC, Staessen JA, et al. Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Stat Med 2008 27 : 1870 93.
28. Hawkins N, Scott DA, Woods B. How far do you go? Efficient searching for indirect evidence. Med Decis Making (in press).